Sector News

Perrigo To Acquire Leading OTC Brands From GSK In All-cash Deal

June 3, 2015
Life sciences
(RTTNews) – Perrigo Company plc announced it has entered into an agreement to acquire a portfolio of over-the-counter brands from GlaxoSmithKline Consumer Healthcare, in connection with GSK’s commitments to divest these businesses in the context of the formation of a consumer health joint venture between GSK and Novartis.
 
The assets include: GSK’s NiQuitin nicotine replacement therapy business, primarily in the European Economic Area and Brazil, and Novartis’s legacy Australian NRT business, including the Nicotinell brand; Several assorted OTC brands including Coldrex across the EEA, and Panodil, Nezeril, and Nasin in Sweden; and Novartis’s legacy cold sore management products primarily in the EEA, marketed under the brand names Vectavir, Pencivir, Fenivir, Fenlips and Vectatone.
 
Perrigo expects the acquisition to be immediately accretive to its calendar 2015 adjusted earnings per share, excluding estimated intangible amortization and transaction-related costs. The transaction is expected to close in the third quarter of 2015.

comments closed

Related News

July 21, 2024

CordenPharma invests €900m in peptide platform expansion

Life sciences

CordenPharma announced its largest strategic investment to date, committing to spend ~€900m over the next three years to enhance its peptide technology platform. The planned investment consists of two major expansion initiatives occurring in parallel in the US and Europe, including both existing facilities and new constructions.

July 21, 2024

DSM-Firmenich to sell MEG-3 fish oil business to KD Pharma Group

Life sciences

DSM-Firmenich has announced the sale of its MEG-3 fish oil business to KD Pharma Group, a contract development and manufacturing organisation that is active in pharmaceutical and nutritional lipids. As part of the transaction, DSM-Firmenich will obtain a minority stake of 29% in KD Pharma’s parent company O³ Holding GmbH.

July 21, 2024

Veranova appoints Cécile Maupas as Senior Vice President, Chief Commercial Officer

Life sciences

Veranova, a development and manufacturing of specialist and complex APIs for the pharmaceutica l and biotech sectors, recently announced the appointment of Cécile Maupas as Senior Vice President, Chief Commercial Officer. Cécile will join the executive team and assume responsibility for business development, marketing, project management, commercial operations, and product management.

How can we help you?

We're easy to reach